Publications by authors named "Benjamin Lampson"

Claim this Profile
E
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Burden of Indolent Systemic Mastocytosis in a Managed Care Organization.
Robert S Zeiger, Kevin Y Tse, Qiaowu Li, Mary Saparudin, Sahar S Al-Salman, Benjamin Lampson

J Allergy Clin Immunol Pract· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MASTering systemic mastocytosis: Lessons learned from a large patient cohort.
Kevin Y Tse, Wansu Chen, Eric J Puttock, Shanta Chowdhury, Kerri Miller, Benjamin Lampson

J Allergy Clin Immunol Glob· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare Germline Variants Influence the Development of Chronic Lymphocytic Leukemia.
Benjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, Kiyomi Mashima, Anna Petráčková

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Matthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, Zixu Wang, Jessica C Lowney

Lancet Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Benjamin L Lampson, Jennifer R Brown

Hematol Oncol Clin North Am· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-grade heart block associated with ibrutinib therapy.
Alexander R Vartanov, Benjamin L Lampson, Eric D Jacobsen, Edwin P Alyea, Javid J Moslehi

HeartRhythm Case Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting oncoproteins with a positive selection assay for protein degraders.
Vidyasagar Koduri, Leslie Duplaquet, Benjamin L Lampson, Adam C Wang, Amin H Sabet

Sci Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
For CLL cells, there's no place like home.
Benjamin L Lampson, Jennifer R Brown

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma.
Nilay Sethi, Osamu Kikuchi, James McFarland, Yanxi Zhang, Max Chung, Benjamin Lampson

JCI Insight· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Benjamin L Lampson, Haesook T Kim, Matthew S Davids, Jeremy S Abramson, Arnold S Freedman

Blood Adv· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new triple threat to CLL.
Benjamin L Lampson, Matthew S Davids

Blood· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Benjamin L Lampson, Jennifer R Brown

Expert Rev Hematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Benjamin L Lampson, Jennifer R Brown

Expert Opin Investig Drugs· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Benjamin L Lampson, Lijian Yu, Robert J Glynn, Jacqueline C Barrientos, Eric D Jacobsen

Blood· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Benjamin L Lampson, Matthew S Davids

Curr Hematol Malig Rep· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
Benjamin L Lampson, Mizuki Nishino, Suzanne E Dahlberg, Danie Paul, Abigail A Santos

Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CLINICAL PROBLEM-SOLVING. Tip of the Tongue.
Benjamin L Lampson, Stacy W Gray, Edmund S Cibas, Bruce D Levy, Joseph Loscalzo

N Engl J Med· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Benjamin L Lampson, Siddha N Kasar, Tiago R Matos, Elizabeth A Morgan, Laura Rassenti

Blood· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
Jamie D Weyandt, Benjamin L Lampson, Sherry Tang, Matthew Mastrodomenico, Diana M Cardona

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare codons capacitate Kras-driven de novo tumorigenesis.
Nicole L K Pershing, Benjamin L Lampson, Jason A Belsky, Erin Kaltenbrun, David M MacAlpine

J Clin Invest· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare codons regulate KRas oncogenesis.
Benjamin L Lampson, Nicole L K Pershing, Joseph A Prinz, Joshua R Lacsina, William F Marzluff

Curr Biol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis